Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Monday that its third quarter revenues skyrocketed 300 percent year over year due to growth in the firm's DecisionDx- Melanoma test report volume.

For the three months ended Sept. 30, the skin cancer test developer reported total revenues of $14.8 million, up from $3.7 million during the same period a year earlier and beating analysts' average estimate of $9.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.